Telomir Pharmaceuticals, Inc. announced on February 5, 2026, new findings showing that their compound, Telomir-Zn, effectively modulates zinc and iron levels in cells, potentially reducing oxidative stress linked to cancer and aging. This study supports ongoing research efforts and plans for an Investigational New Drug application in early 2026.